Clearly you have no expertise in this area.

WPATH has been around since 1979. They are the world's foremost authority on the subject. And they strongly disagree with the Cass Report. Their Standards of Care recommendations are thoroughly grounded in science.

Part of their public statement:

"In contrast to what the Cass Review recommends, WPATH and USPATH firmly stand

by the Standards of Care for the Health of Transgender and Gender Diverse People –

version 8, which was published in 2022—and based on far more systematic reviews

that the Cass Review—in collaboration with The School of Evidence-based Practice

Center at Johns Hopkins University and considers that the (research and consensusbased) evidence is such to recommend that providing medical treatment including

puberty-blocking medication and hormone therapy is helpful and often life-saving for

young TGD people, while withholding such treatment may lead to increased gender

dysphoria and adversely affect psychological functioning. Of note, many countries

have reacted critically regarding the Cass Review, disagreeing with its unfounded

medical opinion to severely limit the use of puberty-blocking medication and

hormone therapy for TGD young people. These countries include Canada, the

Netherlands, Belgium, Germany, Austria, Switzerland, and many states in the United

States. In Germany, a new guideline on adolescent transgender care has been

drafted (in collaboration with Austria and Switzerland) and is currently under review

by 27 professional societies. As drafted, this guideline does not restrict puberty

blockers and is in broad accordance with the WPATH SOC8 recommendations in its

adolescent chapter. The Cass Review appears to be an outlier, ignoring more than

three decades of clinical experience in this area as well as existing evidence showing

the benefits of hormonal interventions on the mental health and quality of life of

gender diverse young people (1-9)."